Huadong Medicine's (SHE:000963) unit, Hangzhou Sino-US Huadong Pharmaceutical, will conduct Phase I clinical trials on HDM2005 for injection in the US after receiving the approval of the country's Food and Drug Administration, according to the company's filing on the Shenzhen Stock Exchange.
The drug will be tested as an antibody-drug conjugate targeting tumors, the Monday filing added.
Shares of the company slipped more than 1% at the close.
Price (RMB): ¥27.69, Change: ¥-0.41, Percent Change: -1.46%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments